Phase I Clinical Trial for Advanced Solid Tumors.
ADC Therapeutics SA of those affected by cancer with its next-generation, targeted antibody drug conjugates for patients with hematologic malignancies and solid tumors, today announced the first patient has been dosed in the Phase 1 clinical trial evaluating ADCT-901, targeting kidney associated antigen 1 (KAAG1), in patients with selected advanced solid tumors with high unmet medical needs.
“With the FDA’s clearance of the IND application for ADCT-901, we are pleased to quickly move this promising new antibody drug conjugate into clinical development,” said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. “There is a high expression of KAAG1 in tumors that have few new medicines, such as ovarian and triple negative breast cancer. We look forward to further evaluating the safety, antitumor activity and optimal dosing for ADCT-901 in this Phase 1 trial.”
ADCT-901 is composed of a humanized monoclonal antibody directed against human KAAG1 conjugated through a cathepsin-cleavable linker to the PBD dimer SG3199, the same cytotoxin used in ADC Therapeutics’ lead product, ZYNLONTA®. KAAG1 is an attractive, novel tumor target for ADCs expressed on the membrane of tumor cells, while its expression on healthy tissue is very limited.
The open-label, dose-escalation and dose-expansion clinical trial will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-901 as monotherapy in patients with selected advanced solid tumors.